Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07787169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 1
Started2026-09
View on ClinicalTrials.gov ↗
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).

Amendment record

Amended once since 2026-08-24. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-25
Amendment Study Status, Study Description v1
2026-08-24
Original filing
Trial Details
NCT Number NCT07787169
Lead Sponsor Eli Lilly and Company
Conditions Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Enrollment 179 participants
Start Date 2026-09
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-27